top of page

Human Pluripotent Stem Cell-based Precision Medicine and Therapies for Heart Diseases

Date: December 3, 2018 (Monday)

Time: 9:00 a.m. – 6:00 p.m.

Venue: Rayson Huang Theatre, The University of Hong Kong, Pokfulam Road, Hong Kong

Co-organized by

Dr. Li Dak-Sum Research Centre, The University of Hong Kong

Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Hong Kong

Dr. Li Dak-Sum Research Centre, the University of Hong Kong and Ming Wai Lau Centre for Reparative Medicine, Karolinska Institutet, Hong Kong are pleased to invite friends, colleagues and students in the fields of regenerative medicine, cardiology and bioengineering to join our symposium on heart regeneration.

This year’s symposium will feature a full day program where scientists from academia and industry around the world will meet and deliver talks on important themes within the scope of regenerative medicine, precision medicine and novel drug discovery.

The symposium will cover a broad range of topics in the field of cardiac regenerative medicine, ranging from novel model systems to unravel human heart diseases, regenerative cardiology, modeling of cardiovascular diseases with stem cell-based models, to novel bioengineering technologies, bioartificial heart tissues and translational bench to bedside regenerative medicine.

Programme Rundown





Session I: Cell-Based Cardiac Therapies

09:15 – 09:45

Gene therapy & genome editing for acquired and experimental heart failure

Roger Hajjar

Director, Cardiovascular Research Center

Arthur & Janet C. Ross Professor of Medicine, Icahn School of Medicine at Mount Sinai

09:45 – 10:15

The potential of human induced pluripotent stem cells to model and to treat congenital heart disease

Yiu-fai Cheung

Bryan Lin Professor in Paediatric Cardiology

Clinical Professor

Department of Paediatrics and Adolescent Medicine, LKS Faculty of Medicine, The University of Hong Kong

10:15 – 10:45

Development of banking and testing protocols for GMP hiPSC

Jo Mountford

Head of Cellular Therapeutics, Tissues Cells and Advanced Therapies, Scottish National Blood Transfusion Service

Hon. Associate Professor, Institute of Cardiovascular and Medical Sciences, University of Glasgow

10:45 – 11:15

Predicting individual arrhythmogenic risk at the individual level using hiPSC

Jean-Sébastien Hulot

Team Leader, Clinical & Translational Investigation Center, Hôpital Européen Georges-Pompidou (Hôpitaux Universitaires Paris-Ouest)

Paris Cardiovascular Research Center PARCC / INSERM

11:15 – 11:30


Session II: Tissue Engineering and Drug Discovery

11:30 – 12:00

Engineering cardiac tissue and development

Peter Zandstra

Director, School of Biomedical Engineering, The University of British Columbia

12:00 – 12:30

A tissue-engineered scale model of the heart ventricle

Luke MacQueen/Kit Parker

Postdoctoral Fellow/Professor

Bioengineering in the Wyss Institute, Harvard University

12:30 – 13:00

Small molecule drug discovery, transitioning from industry to academia:

SERCA2a SUMO activators for heart failure

Robert DeVita

Director of Medicinal Chemistry, Drug Discovery Institute

Professor, Department of Pharmacological Sciences

Icahn School of Medicine at Mt. Sinai, New York, NY

13:00 – 14:30


Session III: Drug and Therapeutics Safety and Discovery in Industry

14:30 – 15:00

Stem cell cardiomyocytes in drug discovery and development - are we there yet?

Bernard Fermini

Co-Chair, CiPA Ion Channel Working Group of the U.S. Food and Drug Administration

15:00 – 15:30

New challenges in safety pharmacology

Sonja Stoelzle-Feix

Director Scientific Affairs at Nanion Technologies

Co-chair of the CiPA Ion Channel Working Group

15:30 – 16:00

Toward a precision medicine approach to drug screening using Novoheart’s hPSC-based MyHeartTM Platform

Kevin Costa

Co-funder and Chief Scientific Officer, Novoheart

16:00 – 16:30

Collaborating to create engineered human tissues using 3D bioprinting technology

Tamer Mohamed

President and Chief Executive Officer, Aspect Biosystems

16:30 – 16:45


Session IV: Commercializing Regenerative Medicine and Therapeutics

16:45 – 17:15

Scale-up of pluripotent stem cell production to enable translation and commercialization

Emily Titus

Vice President. Technology Advancement, Centre for Commercialization of Regenerative Medicine (CCRM)

17:15 – 17:45

Where is Hong Kong in developing precision medicine?

Sabrina Chan

Senior Executive Director, The Hong Kong Association of the Pharmaceutical Industry

17:45 – 18:00


Registration and Enquiries

Registration is free. Please click the following link for online registration:

For enquiries, please contact Dr. Thomas Leon at

CME points would be granted for local participants.


bottom of page